BridgeBio
BridgeBio is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers with genetic drivers, utilizing a decentralized structure and strategic partnerships to enhance drug development efficiency.
Services
BridgeBio develops transformative medicines specifically targeting genetic diseases and cancers with clear genetic drivers. The company employs a patient-centric approach in its clinical and regulatory strategies, focusing on efficiency and speed. It operates a decentralized corporate structure and a hub-and-spoke model through affiliate companies dedicated to developing therapies for specific diseases. In addition, BridgeBio offers Early Access Programs (EAP) and patient assistance programs to ensure timely and broad access to their innovative drug therapies.
Products
BridgeBio has successfully commercialized multiple products aimed at addressing rare and severe conditions. Notable among these are NULIBRY (fosdenopterin), which is used for the treatment of MoCD Type A, and TRUSELTIQ (infigratinib) for FGFR-driven cholangiocarcinoma. These products exemplify the company's commitment to translating scientific discoveries into effective treatments for patients with significant unmet medical needs.
Sector
BridgeBio operates in the biotech and pharmaceuticals sector, focusing on innovative genetic medicines. The company targets genetic diseases and cancers with defined genetic drivers, utilizing cutting-edge drug engineering platforms including molecular dynamics-assisted chemistry and gene therapy. Its approach integrates patient-centric clinical and regulatory strategies to accelerate the path from discovery to market.
Global Clinical Development Footprint
BridgeBio maintains a global clinical development presence, conducting ongoing trials in five different therapeutic areas across more than 25 countries. This extensive footprint underscores the company's commitment to developing and delivering genetic medicines on a worldwide scale. By engaging in strategic partnerships, BridgeBio accelerates the development and commercialization of its products, ensuring that innovative therapies reach patients as swiftly as possible.
Strategic Partnerships and Capital
BridgeBio collaborates strategically with various partners to expedite the development and commercialization of its products. These partnerships are pivotal in leveraging additional expertise and resources, enhancing the efficiency of the drug development process. The company has also secured significant capital to support its ambitious goals of developing and launching genetic medicines, ensuring sustained advancement in its innovative therapeutic solutions.